Verastem Inc. (VSTM)

3.33
NASDAQ : Health Technology
Prev Close 3.24
Day Low/High 3.22 / 3.37
52 Wk Low/High 2.61 / 10.35
Avg Volume 2.87M
Exchange NASDAQ
Shares Outstanding 73.86M
Market Cap 239.32M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data At The 23rd Annual International Congress On Hematologic Malignancies

Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data At The 23rd Annual International Congress On Hematologic Malignancies

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that three COPIKTRA...

New 52-Week Low Could Prompt More Insider Buying At VSTM

New 52-Week Low Could Prompt More Insider Buying At VSTM

In trading on Thursday, shares of Verastem Inc touched a new 52-week low of $2.61/share. That's a $7.74 share price drop, or -74.78% decline from the 52-week high of $10.35 set back on 09/04/2018.

Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) In Patients With CLL/SLL Who Have Progressed Following Two Prior Lines Of Therapy

Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) In Patients With CLL/SLL Who Have Progressed Following Two Prior Lines Of Therapy

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced a poster highlighting...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 239,000 shares of its...

Verastem Oncology To Announce Fourth Quarter And Full-Year 2018 Financial Results And Corporate Update On March 12, 2019

Verastem Oncology To Announce Fourth Quarter And Full-Year 2018 Financial Results And Corporate Update On March 12, 2019

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will...

Verastem Oncology To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Verastem Oncology To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 8 th Annual SVB...

Verastem Oncology Announces Key Management Appointments

Verastem Oncology Announces Key Management Appointments

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced several key...

Verastem Oncology Announces Publication Of The Phase 2 DYNAMO Study Results In Indolent Non-Hodgkin Lymphoma In The Journal Of Clinical Oncology

Verastem Oncology Announces Publication Of The Phase 2 DYNAMO Study Results In Indolent Non-Hodgkin Lymphoma In The Journal Of Clinical Oncology

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the results of...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) ("Verastem Oncology" or "the Company"), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 46,000 shares of its...

2 Small-Cap Biotech Stocks That Are on My Radar

2 Small-Cap Biotech Stocks That Are on My Radar

These high risk/high reward oncology names look significantly undervalued, right now.

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 19,467 shares of its...

Verastem Oncology Outlines Strategic Priorities For 2019 And Highlights Recent Progress

Verastem Oncology Outlines Strategic Priorities For 2019 And Highlights Recent Progress

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today highlighted the company's recent...

Verastem Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Verastem Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 37 th Annual J.

Verastem Oncology Added To The NASDAQ Biotechnology Index®

Verastem Oncology Added To The NASDAQ Biotechnology Index®

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that it has been selected for...

Verastem Oncology Announces First Recipient Of The Care Differently Award For Excellence In Patient Support And Education

Verastem Oncology Announces First Recipient Of The Care Differently Award For Excellence In Patient Support And Education

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, awarded the first annual Care Differently...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 83,978 shares of its...

Verastem Oncology Presents Duvelisib Development Program Data At The American Society Of Hematology 2018 Annual Meeting

Verastem Oncology Presents Duvelisib Development Program Data At The American Society Of Hematology 2018 Annual Meeting

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the presentation of seven posters highlighting new and...

Verastem Oncology Announces Presentation Of Updated Duvelisib Combination Clinical Data In Peripheral T-Cell Lymphoma At The American Society Of Hematology 2018 Annual Meeting

Verastem Oncology Announces Presentation Of Updated Duvelisib Combination Clinical Data In Peripheral T-Cell Lymphoma At The American Society Of Hematology 2018 Annual Meeting

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced an oral presentation highlighting new clinical data from...

First Week Of VSTM January 2019 Options Trading

First Week Of VSTM January 2019 Options Trading

Investors in Verastem Inc saw new options begin trading this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new January 2019 contracts and identified the following put contract of particular interest.

VSTM: Insiders Vs. Shorts

VSTM: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Verastem Inc is one of the most shorted stocks of the Russell 3000, based on 7.68 "days to cover" versus the median component at 4.44. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Verastem Oncology Reports Third Quarter 2018 Financial Results

Verastem Oncology Reports Third Quarter 2018 Financial Results

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today reported financial results for the third quarter ended September...

Verastem Oncology Announces Collaboration With The Leukemia & Lymphoma Society To Accelerate Development Of Duvelisib For The Treatment Of Peripheral T-Cell Lymphoma

Verastem Oncology Announces Collaboration With The Leukemia & Lymphoma Society To Accelerate Development Of Duvelisib For The Treatment Of Peripheral T-Cell Lymphoma

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a collaboration with The Leukemia & Lymphoma Society®...

Verastem Oncology Announces Presentation Of Preclinical Data Supporting Dual PI3K-delta And PI3K-gamma Inhibition In Combination With Immunotherapy At The Society For Immunotherapy Of Cancer's 33rd Annual Meeting

Verastem Oncology Announces Presentation Of Preclinical Data Supporting Dual PI3K-delta And PI3K-gamma Inhibition In Combination With Immunotherapy At The Society For Immunotherapy Of Cancer's 33rd Annual Meeting

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a poster presentation of preclinical data by Jonathan...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 6,153 shares of its...

Verastem Enters Oversold Territory (VSTM)

Verastem Enters Oversold Territory (VSTM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Verastem Oncology Announces Data Presentations At The American Society Of Hematology 2018 Annual Meeting

Verastem Oncology Announces Data Presentations At The American Society Of Hematology 2018 Annual Meeting

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that eight abstracts have been selected for presentation,...

The Power of Personalization: Cramer's 'Mad Money' Recap (Thursday 9/27/18)

The Power of Personalization: Cramer's 'Mad Money' Recap (Thursday 9/27/18)

Jim Cramer says you need to understand the theme behind the market's action, but also you need to know the timing.

Ferrari, Paychex, First American: 'Mad Money' Lightning Round

Ferrari, Paychex, First American: 'Mad Money' Lightning Round

Jim Cramer weighs in on Ferrari, Paychex, First American, Verastem, Halliburton and more.